Get the Stockscreener App
147.30
0.56%
0.82
Pre-market:
147.30
Icon Plc stock is traded at $147.30, with a volume of 1.81M.
It is up +0.56% in the last 24 hours and up +15.09% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$146.48
Open:
$145.75
24h Volume:
1.81M
Relative Volume:
1.25
Market Cap:
$11.50B
Revenue:
$8.19B
Net Income/Loss:
$758.19M
P/E Ratio:
16.05
EPS:
9.18
Net Cash Flow:
$1.06B
1W Performance:
+0.18%
1M Performance:
+15.09%
6M Performance:
-29.86%
1Y Performance:
-53.79%
1-Day Range:
$145.48
$149.49
1-Week Range:
$140.20
$149.49
52-Week Range:
$125.10
$347.72
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
147.30 | 11.50B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
400.21 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.34 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
524.65 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.13 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
155.17 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
ICON plc Reports Strong Interim Financial Results for Early 2025 - TipRanks
Medical Device Regulatory Affairs Market Top PlayersICON, - openPR.com
ICON plc Announces 2025 AGM and Key Resolutions - TipRanks
Icon PLC (ICLR) Shares Up 3.47% on Jun 6 - GuruFocus
Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - GlobeNewswire Inc.
ICON Public Limited (NASDAQ:ICLR) Short Interest Up 25.4% in May - Defense World
Icon PLC (ICLR) Stock Price Up 4.49% on Jun 4 - GuruFocus
ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review - mx.advfn.com
Here's Why You Should Retain ICLR Stock in Your Portfolio Now - TradingView
Icon PLC (ICLR) Down 9.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
ICON plc to Present at the William Blair 45th Annual Growth Stoc - GuruFocus
ICON plc to Present at Annual Growth Stock Conference By Investing.com - Investing.com South Africa
ICLR December 2026 Options Begin Trading - Nasdaq
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference - BioSpace
ICON plc to Present at Annual Growth Stock Conference - Investing.com
ICON plc to Present at William Blair Growth Stock Conference - TipRanks
ICON’s SWOT analysis: cro stock faces headwinds amid potential rebound - Investing.com
ICON Life Science Internship For BSc & MSc – Applications Closing Soon! Hurry! - BioTecNika
Redburn Atlantic Adjusts Icon (ICLR) Price Target Amid Market Uncertainty | ICLR Stock News - GuruFocus
ICON Plc stock hits 52-week low at $127.51 amid market challenges By Investing.com - Investing.com South Africa
ICON Plc stock hits 52-week low at $127.51 amid market challenges - Investing.com Nigeria
ICON releases its ICON Cares 2024 Report | ICLR Stock News - GuruFocus
ICON releases its ICON Cares 2024 Report - Silicon Canals
ICON Releases ICON Cares 2024 Report Highlighting ESG Achievements - TipRanks
Icon (ICLR) Maintains Outperform Rating Amid Price Target Adjustment | ICLR Stock News - GuruFocus
Icon (ICLR) Price Target Reduced by Mizuho to $173 | ICLR Stock News - GuruFocus
Daily Progress: Icon Plc (ICLR) Drop -5.54, Closing at 135.10 - DWinneX
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies | ICLR Stock News - GuruFocus
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies - Business Wire
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR S - GuruFocus
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR Stock News - GuruFocus
ICON plc (ICLR) Consensus: A 29% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Icon Plc Earnings Call: Navigating Challenges and Opportunities - TipRanks
Icon (ICLR) Sees Price Target Adjustment by Barclays | ICLR Stock News - GuruFocus
ICON plc Expands Share Buyback Program Amid Vaccine Study Delays and Tariff Uncertainty - TipRanks
Icon Plc [ICLR] Officer makes an insider purchase of 1,540 shares worth 0.29 million. - knoxdaily.com
Market Analysts see Icon Plc [ICLR] gaining to $150. Time to buy? - dbtnews.com
Icon (ICLR) Price Target Reduced by BofA Analyst | ICLR Stock Ne - GuruFocus
ICLR Faces Revenue Pressure Amid Elevated Cancellations - GuruFocus
Barclays Adjusts Price Target for Icon (ICLR) Amid Uncertain Out - GuruFocus
Barclays Adjusts Price Target for Icon (ICLR) Amid Uncertain Outlook | ICLR Stock News - GuruFocus
Icon PLC (ICLR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - Yahoo Finance
ICON Public Limited Company (NASDAQ:ICLR) Q1 2025 Earnings Call Transcript - MSN
ICON plc Reports Q1 2025 Financial Results - TipRanks
Icon Earnings: Macroeconomic Issues and Trial Delays Affect Our Near-Term View - Morningstar
Narrow-Moat Icon Faces Macroeconomic Issues and Trial Delays That Constrain Its Near-Term Outlook - Morningstar
The Future of Icon Plc: Analyzing ICLR - investchronicle.com
A look at ICLR’s current quarter earnings estimates - uspostnews.com
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down - Yahoo Finance
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):